Home With $450M sale, Alnylam has more cash than any pre-commercial biotech
 

Keywords :   


With $450M sale, Alnylam has more cash than any pre-commercial biotech

2015-01-20 19:26:36| Biotech - Topix.net

Thanks to a massive infusion of cash a year ago from neighboring Genzyme , Alnylam Pharmaceuticals already has more cash and other assets that can be easily converted into cash than any other biotech with no products on the market in the U.S. With a $450 million offering announced today, it will soon have about 50 percent more. Alnylam 's shares were down only slightly today - about 3 percent to $97.44 as of noon - after announcing the secondary stock offering, easily among the biggest in biotech in the past several years.

Tags: sale cash biotech 450m

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
05.11Tropical Storm Rafael Public Advisory Number 9
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 9
05.11Kim Madigan to chair 2025 FTA Fall Technical Conference
05.11PM responds to Sir Alan Bates after repeated requests
More »